Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals raises 2025 revenue guidance to $768-793 million in investor deck

Positive Impact 3 of 5 guidance Written later

ANI Pharmaceuticals filed an investor presentation for the H.C. Wainwright BioConnect conference on May 20, 2025, where CEO Nikhil Lalwani is scheduled to present. The deck restates the revised full-year 2025 guidance issued May 9, 2025, which raised net revenue to $768-793 million from $756-776 million and adjusted EBITDA to $195-205 million from $190-200 million, and describes this as the second guidance raise this year.

Key points

  • Full-year 2025 net revenue guidance is $768-793 million, up from $756-776 million; the deck calls this the second guidance raise in 2025.
  • Adjusted non-GAAP diluted EPS guidance is $6.27-6.62, up from $6.12-6.49.
  • Q1 2025 total revenue was $197 million, up 43% year over year; Q1 adjusted non-GAAP EBITDA was $51 million, up 35%.
  • CEO Nikhil Lalwani will present on May 20, 2025 at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECMay 20, 2025, 8:05 AM ET
Accession number0001023024-25-000049

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.